Effect of Nusinersen on Adults With Spinal Muscular Atrophy
NCT03878030 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12
Last updated 2023-03-20
Summary
Observational study of adult patients with spinal muscular atrophy types 2 and 3 receiving nusinersen
Conditions
- Adult Spinal Muscular Atrophy
Interventions
- DRUG
-
nusinersen
Subjects will receive nusinersen and be observed with motor assessments for 24 months
Sponsors & Collaborators
-
Northwell Health
lead OTHER
Principal Investigators
-
Anthony Geraci, MD · Northwell Health
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-04-01
- Primary Completion
- 2021-07-13
- Completion
- 2021-07-13
Countries
- United States
Study Locations
More Related Trials
-
Antisense Oligonucleotide for Spinal Muscular Atrophy
NCT05187260 ·Status: UNKNOWN
-
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)
NCT02292537 ·Status: COMPLETED ·Phase: PHASE3
-
Pulmonary Function Test Changes and Respiratory Muscle Strength Trends in Spinal Muscular Atrophy Patients Receiving Nusinersen Treatments
NCT04050852 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Personalized Medicine for SMA: a Translational Project
NCT05779956 ·Status: UNKNOWN
-
Ultrasound-assisted vs Landmark Based Intrathecal Administration of Nusinersen
NCT04674618 ·Status: COMPLETED ·Phase: NA
-
A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
NCT04729907 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA
NCT06955897 ·Status: RECRUITING
-
An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)
NCT02052791 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).
NCT02462759 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)
NCT04488133 ·Status: COMPLETED ·Phase: PHASE4
-
Metabolomics of Children With SMA
NCT04587492 ·Status: COMPLETED
-
An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)
NCT01494701 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
NCT05067790 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy
NCT01703988 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy
NCT05337553 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
NCT02386553 ·Status: COMPLETED ·Phase: PHASE2
-
A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies
NCT02594124 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
NCT05789758 ·Status: RECRUITING
-
The Effect of Aerobic Exercise Training in Patients With Type III Spinal Muscular Atrophy
NCT05544994 ·Status: UNKNOWN ·Phase: NA
-
Ultrasound-assisted or Landmark-based Intrathecal Administration of Nusinersen in Adult Patients With Spinal Muscular Atrophy (The EchoSpin Study)
NCT05644899 ·Status: COMPLETED
-
Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)
NCT02865109 ·Status: NO_LONGER_AVAILABLE
-
Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies
NCT06532474 ·Status: RECRUITING
-
Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®
NCT04159987 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Responsiveness and Validation Study of MFM-32 in SMA Patients Treated With Nusinersen
NCT04602195 ·Status: COMPLETED
-
Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study
NCT05839145 ·Status: NOT_YET_RECRUITING ·Phase: NA